clinical trial · NCT07629583
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Genentech, Inc.·phase1·recruiting·n = 46
Lupus Erythematosus, SystemicCevostamabTocilizumab
brief summary
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
started
Oct 31, 2026
primary completion
Mar 29, 2030
completion
Mar 29, 2030
last updated
Sep 8, 2026
official title
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol